DUBLIN, December 5, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/str4n4/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering.
A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L.
Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs. The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of the measurement of enzymes to reduce operational error.
The analysts forecast the Global Cardiac Biomarkers market to grow at a CAGR of 12.75 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Cardiac Biomarkers market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of devices and assays used for cardiac biomarkers to diagnose various cardiovascular diseases.
The identification of new cardiac biomarkers (H-FABP, GPBB, Urotensin II, and S-100 as potential cardiac biomarkers) and the advances being made in diagnostic technologies are some of the major trends uocoming in this market.
According to the report, one of the major factors driving this market is the increase in the incidence of cardiac disorders. This increase in the incidence of CVDs, HF, and coronary syndromes is leading to increased adoption of cardiac POC tests because they provide rapid diagnostics for analyzing the specificity of the disease.
Further, the report states that one key challenge in the market is the lack of specific measures to detect the presence of CVDs, which may have an adverse effect on patients because it may lead to incorrect diagnosis, and in serious cardiac conditions it may even cause death
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Market Segmentation by Type of Assay
08. Global Troponin Assay Market
09. Global BNP & NT-proBNP Assay Market
10. Global CK-MB Assay Market
11. Global Myogloblin Assay Market
12. Market Segmentation by End-user
13. Global Cardiac Laboratory Testing Market
14. Geographical Segmentation
15. Key Leading Countries
16. Buying Criteria
17. Market Growth Drivers
18. Drivers and their Impact
19. Market Challenges
20. Impact of Drivers and Challenges
21. Market Trends
22. Trends and their Impact
23. Vendor Landscape
24. Key Vendor Analysis
- Abbott Laboratories
- BG Medicine
- Beckman Coulter
- Boston Scientific
- Critical Diagnostics
- Dickinson and Co.
- Mitsubishi ChemicalEurope
- Ortho Clinical Diagnostics
- Radiometer Medical
- Randox Laboratories
- Response Biomedical
- Roche Diagnostics
- Siemens Healthcare
- Sierra Resources International
- Thermo Scientific
- Trinity Biotech
For more information visit http://www.researchandmarkets.com/research/str4n4/global_cardiac
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets